Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 41

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 41
---
 Under the Tumim Registration Rights Agreement, we agreed to file a resale Registration Statement covering the Resale Shares within 30 calendar days after the date of the Tumim Registration Rights Agreement, and to use commercially reasonable efforts to cause such resale Registration Statement to be declared effective by the SEC as soon as reasonably practicable after the filing thereof, but in any event no later than the forty-fifth 25

calendar day after the earlier of (1) the date on which this registration statement is filed and (2) August 21, 2025 (the filing deadline being thirty calendar days from the closing date, July 22, 2025) (the “Effectiveness Date”); provided, however, that in the event we are notified by the SEC that the resale Registration Statement will not be reviewed or is no longer subject to further review, the Effectiveness Date will be the third trading day following the date on which we are so notified if such date precedes the dates otherwise required above.

<div align='center'>26</div>

RISK FACTORS Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled “Cautionary Note Regarding Forward-Looking Statements”. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. Risks Related to our Limited Operating History, Financial Condition and Capital Requirements We currently have three commercial products, ZTlido, ELYXYB and GLOPERBA; but we are currently heavily dependent on the commercial success of ZTlido, as ELYXYB and GLOPERBA are in the initial stages of commercialization, and we may be unable to generate sufficient revenue to support our operations. We currently have three commercial products, ZTlido, ELY